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Abstract
Little evidence exists to evaluate the effectiveness of ﬁrst-line tyrosine kinase inhibitors in the community
setting. Through electronic health records, 300 chronic myeloid leukemia patients were identiﬁed. Similar to
clinical trials, dasatinib and nilotinib had higher cytogenetic and molecular responses and faster molecular
responses than imatinib in a community setting. Frequency of response monitoring was lower than recom-
mended in the guidelines.
Background: Clinical outcomes of patients with chronic myeloid leukemia (CML) treated in clinical trials, including
response to therapy, may not be representative of those treated in a community setting. Thus, we sought to determine
the real-world effectiveness of ﬁrst-line tyrosine kinase inhibitors in CML by evaluating response rates, all-cause
discontinuation, and adherence. Response monitoring patterns were also analyzed. Patients and Methods: This
retrospective observational study, using the McKesson Specialty Health/US Oncology Network (MSH/USON)
iKnowMed electronic health record database and medical charts, identiﬁed newly diagnosed CML patients who
received ﬁrst-line imatinib, dasatinib, or nilotinib from July 2007 to March 2011, and were then followed for  18
months. Results: Three hundred patients met study criteria (222 imatinib-treated, 34 dasatinib-treated, and 44
nilotinib-treated in the ﬁrst-line). Molecular and cytogenetic response assessments were conducted less frequently
than recommended (40% never had cytogenetic or molecular monitoring at any time). Patients treated with either
dasatinib or nilotinib experienced higher response rates by 6, 12, and 18 months, faster time to major molecular
response, and a signiﬁcantly lower rate of all-cause treatment discontinuation within 18 months relative to imatinib-
treated patients. Approximately 56% of all patients were adherent to tyrosine kinase inhibitor therapy. Conclusion:
Dasatinib and nilotinib were more effective than imatinib as ﬁrst-line therapy for CML in a community setting, as
observed in descriptive and univariate analyses. The frequency of cytogenetic and molecular monitoring was lower
than that recommended by current guidelines, including patients with no molecular or cytogenetic assessments during
the 18-month follow-up. Therefore, MSH/USON is working toward improving compliance with response monitoring
guidelines.
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Tyrosine kinase inhibitors (TKIs) have revolutionized the treat-
ment of chronic myeloid leukemia (CML), dramatically improving
the prognosis of treated patients.1-8 Three TKIs are currently
approved for ﬁrst-line treatment of CML in the chronic phase
(CML-CP): imatinib, dasatinib, and nilotinib.9-11 Imatinib was the
ﬁrst TKI approved for the treatment of newly diagnosed patients
with CML-CP9; however, resistance and intolerance account for a
signiﬁcant number of patients unable to continue treatment.1,12
The second-generation TKIs dasatinib and nilotinib were then
developed to treat patients with CML-CP in whom imatinib ther-
apy had failed.10,11
In the DASISION (Dasatinib vs. Imatinib Study in Treatment-
Naive CML Patients) trial, dasatinib showed superior efﬁcacy over
imatinib in newly diagnosed patients with CML-CP, leading to its
ﬁrst-line approval.2-4,10 Speciﬁcally, the rate of conﬁrmed complete
cytogenetic response (CCyR) by 12 months was signiﬁcantly higher
with dasatinib than with imatinib (77% vs. 66%, P ¼ .007), as was
the rate of major molecular response (MMR) by 12 months (46%
vs. 28%, P < .0001).2 For dasatinib versus imatinib, median time
to MMR was faster with dasatinib (9.2 vs. 15.0 months).4
Nilotinib was also approved for the ﬁrst-line treatment of patients
with CML-CP based on the results of the ENESTnd (Evaluating
Nilotinib Efﬁcacy and Safety in Clinical TrialseNewly Diagnosed
Patients) trial.6-8,11 At 12 months, the rates of MMR for 2 dose
levels of nilotinib (300 mg and 400 mg twice daily) were higher
than that for imatinib (44% and 43% vs. 22%, respectively;
P < .001 for both comparisons), and the rates of CCyR by 12
months were higher with nilotinib as well (80% and 78% vs. 65%,
respectively; P < .001 for both comparisons).6 Median time to
MMR was also faster for nilotinib (8.3 months) compared with
imatinib (11.1 months).7
Response monitoring is critical to the management of CML-CP
in order to identify patients with suboptimal response or resistance
to TKI therapy. The current response monitoring recommendations
from the National Comprehensive Cancer Network (NCCN) CML
guidelines support molecular testing via quantitative real-time
polymerase chain reaction (qPCR) using the International Scale
(IS) every 3 months for patients responding to treatment, every
3 months for 3 years once CCyR has been achieved, and then every
3 to 6 months.13 Bone marrow cytogenetics are recommended at 3
and 6 months if qPCR is not available, at 12 months if CCyR or
MMR are not achieved, and at 18 months if the patient had not
previously achieved CCyR or MMR at 12 months.13 European
LeukemiaNet (ELN) guidelines similarly recommend frequent
monitoring.14
Molecular monitoring as recommended by the current guidelines
is also associated with increased adherence to TKI therapy, and this
may have signiﬁcant clinical implications.15 Adherence to TKIs is
essential for the achievement of durable hematologic, cytogenetic,
and molecular responses. In clinical studies of imatinib-treated pa-
tients, nonadherence has been shown to contribute to the failure to
achieve CCyR, MMR, and complete molecular response.16,17
However, there is a lack of quantitative information available
regarding adherence to TKI therapy and its association with clinical
response in the community setting.Clinical Lymphoma, Myeloma & Leukemia October 2015Patients who are appropriately monitored outside of clinical trials
may have similar outcomes to those enrolled in trials18; however,
monitoring in the community setting appears to be less frequent
than guidelines recommended by the NCCN and ELN.19-22 In the
present analysis, the effectiveness of ﬁrst-line TKIs was investigated
in community-based oncology practices. Speciﬁcally, we evaluated
response rates, adherence, and all-cause discontinuation in patients
with CML. Response monitoring patterns were observed as well.
This study also attempted to provide the groundwork for future
comparative effectiveness assessment among the 3 TKIs, with
further accrual of patients treated with second-generation TKIs in
clinical practice.
Patients and Methods
Patient Population
CA180-508 is a retrospective observational cohort study of pa-
tients with CML treated with imatinib, dasatinib, or nilotinib in the
ﬁrst-line setting in the community clinical practices of the
McKesson Specialty Health/US Oncology Network (MSH/
USON). Patients receiving care at an MSH/USON site between
July 1, 2007, and March 31, 2011, were evaluated for enrollment
criteria.
Patients were eligible for inclusion in the study if they were more
than 18 years old and newly diagnosed with CML, received a TKI
as ﬁrst-line therapy, received care at an MSH/USON practice using
full iKnowMed electronic health record (iKM EHR) capabilities,
and had more than 1 visit recorded during the study period. Only
patients with CML-CP were included in the response analyses.
Patients were excluded from the study if they were enrolled in
clinical trials during the study period or if they were diagnosed with
or treated for other cancers.
Patients were followed for  18 months from the date of
enrollment, and data collected as of September 30, 2012, are
analyzed in the present report. Data were extracted using program-
matic query of MSH/USON’s iKM EHR system, electronic medical
record chart review, and the Social Security Death Master File.
Deﬁnitions
Complete hematologic response was deﬁned as average leuko-
cyte count < 10  109/L, average platelet count < 450  109/L,
and average myelocyte, promyelocyte, and blast count in periph-
eral blood ¼ 0 or missing during 0 to 3, 4 to 6, and 7 to 12
months of follow-up. CCyR was deﬁned as absence of Philadel-
phia chromosomeepositive metaphases as measured by bone
marrow cytogenetics, or < 1% BCR-ABL-positive nuclei by
ﬂuorescence in-situ hybridization. MMR was deﬁned as  3-log
reduction of BCR-ABL mRNA transcripts from baseline, or
BCR-ABL  0.1% on the IS.
Adherence to TKI therapy was estimated as actual days of TKI
therapy divided by total days of recommended therapy, converted to
a percentage, using physician prescription records. Data on pre-
scription ﬁlls and actual use of drug were not available. Patients were
considered adherent if they had  90% adherence.
Progression was deﬁned as the occurrence of bone marrow
transplant, transformation to accelerated phase (AP) or blast phase
(BP), or death.
Table 1 Patient Demographic and Disease Characteristics at
Baseline
Characteristic
First-Generation
TKI (Imatinib;
n [ 222)
Second-Generation
TKIs (Dasatinib/
Nilotinib;
n [ 78)
Median Age, years 56 50
Age Group, n (%)
18-39 years 39 (18) 13 (17)
39-64 years 103 (46) 44 (56)
>64 years 70 (32) 14 (18)
Male, n (%) 119 (54) 40 (51)
Practice Location, n (%)
Central 17 (8) 6 (8)
Northeast 10 (5) 0
Southeast 47 (21) 15 (19)
Southwest 113 (51) 46 (59)
West 24 (11) 9 (12)
Payer, n (%)
Private 99 (45) 47 (60)
Medicare/managed
Medicare
72 (32) 14 (18)
Self-pay 30 (14) 9 (12)
Other/unknown 16 (7) 5 (6)
Medicaid 5 (2) 3 (4)
Phase, n (%)
Chronic 164 (74) 60 (77)
Accelerated 11 (5) 6 (8)
Blast 3 (1) 0
Unknown 44 (20) 12 (15)
Most Common
Comorbidities, n (%)
CAD 26 (12) 7 (9)
Diabetes 23 (10) 16 (21)
Chronic pulmonary
disease
15 (7) 3 (4)
PVD 12 (5) 4 (5)
CHF 10 (5) 1 (1)
Abbreviations: CAD ¼ coronary artery disease; CHF ¼ congestive heart failure; PVD ¼
peripheral vascular disease; TKI ¼ tyrosine kinase inhibitor.
Nicholas J. Di Bella et alAnalyses
Patients treated with either dasatinib or nilotinib were combined
in these analyses because these second-generation TKIs were only
approved for ﬁrst-line use during the end of the enrollment period,
resulting in small sample sizes.
Descriptive statistics were utilized to summarize demographics,
monitoring frequency, treatment response, adherence, progression,
and hospitalization for all treated patients. Fisher’s exact test was
used to determine the association between adherence and response.
Cumulative cytogenetic or molecular response rates were calcu-
lated among CML-CP patients who were evaluated for cytogenetic
or molecular response only, and measured over 0 to 6, 7 to 12, and
12 to 18 months of follow-up. For this intent-to-treat analysis, some
patients may have achieved CCyR or MMR with a second-line TKI,
and the chi-square test was used to determine the association be-
tween TKI therapy and response. Additionally, cumulative cytoge-
netic and molecular response rates were combined for this analysis
because of small sample sizes, due to the timing of ﬁrst-line ap-
provals of dasatinib and nilotinib and the lack of response moni-
toring. Therefore, it was more meaningful to examine the combined
category to have a larger sample size for comparisons between ﬁrst-
and second-generation TKIs.
The Kaplan-Meier method was used to analyze time to MMR
and time to all-cause treatment discontinuation. For analysis of time
to MMR, CML-CP patients who were evaluated for molecular
response were censored for discontinuation of ﬁrst-line therapy,
initiation of second-line therapy, or end of 18-month follow-up
without MMR (less than MMR or missing molecular response
data), whichever occurred ﬁrst.
Results
Patient Characteristics
Three hundred newly diagnosed patients with CML who met the
study criteria were identiﬁed within the iKM EHR database
(Table 1). Of these patients, 222 were treated with imatinib and 78
with second-generation TKIs (34 with dasatinib and 44 with
nilotinib) in the ﬁrst-line setting. Baseline patient characteristics
were well balanced across the TKIs. The majority of newly diag-
nosed patients (75%) had CML-CP. In addition, 6% had CML-
AP, 1% had CML-BP, and the phase of CML was unknown in
the remainder of patients (19%). The most common comorbidities
present at diagnosis for patients treated with imatinib or dasatinib/
nilotinib, respectively, were coronary artery disease (12% and 9%),
diabetes (10% and 21%), chronic pulmonary disease (7% and 4%),
peripheral vascular disease (5% and 5%), and congestive heart
failure (5% and 1%).
Frequency of Response Monitoring
In order to understand monitoring patterns in the community
setting, the frequency of response testing was captured (Table 2).
The frequency of hematologic response monitoring decreased over
time, with 74% of patients tested within 3 months and 48% tested
at 13 to 18 months. Together, 82% of patients had a hematologic
response monitoring assessment at any time during the study
period.
Cytogenetic and molecular response monitoring assessments were
conducted less frequently than recommended (Table 2).13,14 Theproportion of patients with a cytogenetic monitoring assessment at
any time during the study period was 37%. Forty-seven percent of
patients had molecular assessments at any time during the study
period, and 23% had assessments conducted using the IS. Twenty-
one percent of patients had a molecular assessment within the ﬁrst 3
months of starting treatment. The frequency of molecular moni-
toring ﬂuctuated over time, ranging from 18% of patients tested at
13 to 18 months to 30% of patients tested at 7 to 12 months.
Combined, 60% of patients underwent either a cytogenetic or a
molecular response assessment at any time during the study period.
Fewer patients underwent both a cytogenetic and a molecular
response assessment (24%).Clinical Lymphoma, Myeloma & Leukemia October 2015 - 601
Table 2 Testing Frequency for Assessment of Each Response
Characteristic Patients, n (%)
Hematologic Monitoring
Tested, any time 247 (82)
Tested, 0-3 months 223 (74)
Tested, 4-6 months 188 (63)
Tested, 7-12 months 182 (61)
Tested, 13-18 months 144 (48)
Cytogenetic Monitoring
Tested, any time 111 (37)
By FISH 82 (27)
By bone marrow assessment 70 (23)
Molecular Monitoring
Tested, any time 142 (47)
By BCR-ABL level 125 (42)
By International Scale 68 (23)
By log reduction 39 (13)
Tested, 0-3 months 62 (21)
Tested, 4-6 months 59 (20)
Tested, 7-12 months 91 (30)
Tested, 13-18 months 55 (18)
Cytogenetic and Molecular Monitoring
Tested, any time 72 (24)
Cytogenetic or Molecular Assessment
Tested, any time 181 (60)
Abbreviation: FISH ¼ ﬂuorescence in-situ hybridization.
Figure 1 CCyR or MMR by 6, 12, and 18 Months by First-Line
TKI
Real-World Effectiveness of TKIs in CML
602 -Effectiveness
Responses. The effectiveness of ﬁrst-line TKI therapy in newly
diagnosed patients with CML was investigated. Complete hema-
tologic response was achieved in most CML-CP patients evaluated
for hematologic response assessment at 4 to 6 months, with 89% of
patients treated with the ﬁrst-generation TKI imatinib and 94% of
patients treated with a second-generation TKI (dasatinib or niloti-
nib) achieving complete hematologic response (Table 3).
Cumulative cytogenetic and molecular response rates increased
for both treatment groups with a cytogenetic or molecular responseTable 3 Complete Hematologic Response
Time
Patients,a n/N (%)
First-Generation
TKI (Imatinib)
Second-Generation
TKIs (Dasatinib/
Nilotinib)
At 0-3 months 51/127 (40) 12/44 (27)
At 4-6 months 96/108 (89) 33/35 (94)
At 7-12 months 87/104 (84) 27/33 (82)
Abbreviations: CML ¼ chronic myeloid leukemia; CP ¼ chronic phase; TKI ¼ tyrosine kinase
inhibitor.
aOnly patients with CML-CP who were evaluated for hematologic response were included in this
analysis. Complete hematologic response for each patient for each time period was deﬁned as
follows: average leukocyte count < 10  109/L; average platelet count < 450  109/L; and
average myelocyte, promyelocyte, and blast count ¼ 0 or missing.
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with CML-CP treated with dasatinib/nilotinib versus imatinib by 6,
12, and 18 months (Figure 1). Speciﬁcally, 61% of patients treated
with dasatinib/nilotinib achieved CCyR or MMR by 12 months
compared with 38% of patients treated with imatinib (P ¼ .006).
Although in this intent-to-treat analysis patients in the imatinib-
treated group may have switched to a second-generation TKI,
responses remained signiﬁcantly higher for the patient group treated
with dasatinib/nilotinib ﬁrst. This is despite the inclusion of
responses from a large number of patients switching to a second-
generation TKI in the imatinib group. Time to MMR was
signiﬁcantly faster in patients with CML-CP treated with dasatinib/
nilotinib relative to those who received imatinib (P ¼ .002;
Figure 2).
Progression, Hospitalization, and Time Receiving Treatment. A
total of 37 progression events occurred during the study period:
31 (14%) in the imatinib treatment cohort (bone marrow trans-
plant, 4 patients; transformation to AP or BP, 10 patients; death,
17 patients); and 3 each in the dasatinib (9%; transformation to AP
or BP, 3 patients) and nilotinib (7%; bone marrow transplant, 1
patient; death, 2 patients) treatment groups. A total of 25 patients
were hospitalized during the study period. Fourteen patients (6%)
treated with imatinib were hospitalized (7 for reasons not related to
CML, 6 for CML-related reasons, and 1 for unknown reasons). Six
patients (18%) in the dasatinib treatment arm were hospitalized
(4 for reasons not related to CML, and 2 for unknown reasons).
Five patients (11%) treated with nilotinib were hospitalized (3 for
reasons not related to CML and 2 for CML-related reasons).
Additionally, the time to discontinuation was signiﬁcantly longer
for patients treated with dasatinib/nilotinib relative to imatinib
(P ¼ .003; Figure 3). Seventy-one patients discontinued therapy
because of toxicity (44%), 40 discontinued because of diseaseAbbreviations: CCyR ¼ complete cytogenetic response; CML ¼ chronic myeloid leukemia;
CP ¼ chronic phase; MMR ¼ major molecular response; TKI ¼ tyrosine kinase inhibitor.
aIn this intent-to-treat analysis, only patients with CML-CP who were evaluated for cytogenetic
or molecular response were included, including responses achieved if the patient switched to a
second-line TKI. P values are from chi-square test.
Figure 2 Time to MMR
Abbreviations: CML ¼ chronic myeloid leukemia; CP ¼ chronic phase; MMR ¼ major molecular response (deﬁned as  3-log reduction of BCR-ABL mRNA transcripts from baseline or BCR-ABL
 0.1% on the International Scale); TKI ¼ tyrosine kinase inhibitor.
aOnly patients with CML-CP who were evaluated for molecular response were included in this analysis. Patients were censored for discontinuation of ﬁrst-line therapy, initiation of second-line therapy,
or end of 18-month follow-up without MMR (less than MMR or missing molecular response data), whichever occurred ﬁrst. P value is from log-rank test.
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(17%), and 24 discontinued because of other reasons (15%).
Adherence
Adherence to TKIs is critical for the achievement of durable
responses.16,17 Therefore, adherence to TKIs as well as the associ-
ation between adherence and response to TKI therapy were
analyzed in the community setting in this study (Table 4). Mean
adherence was higher with dasatinib at 87%, followed by 79% withFigure 3 Time to Discontinuation of First-Line TKI
P value is from log-rank test.
Abbreviation: TKI ¼ tyrosine kinase inhibitor.imatinib and 77% with nilotinib. A similar proportion of patients
receiving second-generation TKIs were considered adherent com-
pared with those receiving imatinib, as 55% to 56% of patients in
this analysis had  90% adherence. By 18 months, there was a
trend toward a higher proportion of adherent patients achieving
CCyR or MMR compared with the proportion of nonadherent
patients (46% vs. 43%, respectively; P ¼ .86). However, the
comparison of response by adherence status was limited by the low
frequency of monitoring, resulting in small sample sizes (Table 2).Clinical Lymphoma, Myeloma & Leukemia October 2015 - 603
Table 4 Cytogenetic or Molecular Response by Adherence
Status
Characteristic
Patients, n (%)
PbAdherenta Nonadherent
Adherence by
First-Line TKI
First-generation TKI
(imatinib; n ¼ 169)
95 (56) 74 (44)
Second-generation
TKIs (dasatinib/nilotinib;
n ¼ 60)
33 (55) 27 (45)
Total (n ¼ 229) 128 (56) 101 (44) .87
Complete Cytogenetic
Response or Major
Molecular Response
By 6 months 11 (19) 10 (24) .62
By 12 months 28 (39) 19 (37) .85
By 18 months 33 (46) 23 (43) .86
Abbreviation: TKI ¼ tyrosine kinase inhibitor.
aMean (standard error) adherence was 79.3% (2.2%) for imatinib, 87.3% (3.2%) for dasatinib,
and 76.6% (5.7%) for nilotinib.
bP values are from Fisher’s exact test.
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It is unclear whether responses to therapy and outcomes of
patients with CML treated in clinical trials are representative of
those treated in a community setting. In this retrospective electronic
medical record review, we sought to provide insight into the
effectiveness of ﬁrst-line TKIs beyond clinical trials by reviewing the
response rates, time receiving treatment, and adherence of patients
with CML treated with imatinib, dasatinib, or nilotinib within a
large network of community-based oncology practices.
Overall, patients in the community setting treated with the
second-generation TKIs dasatinib or nilotinib achieved more
favorable responses than those treated with the ﬁrst-generation TKI
imatinib. Notably, rates of CCyR and MMR were signiﬁcantly
higher for patients treated with dasatinib and nilotinib even though
a high number of patients treated with imatinib were switched to a
second-generation TKI, and those responses were counted in this
analysis. These results are consistent with ﬁndings from major ﬁrst-
line clinical trials comparing dasatinib or nilotinib to imatinib
(DASISION and ENESTnd),2-4,6-8 suggesting that the responses of
CML patients receiving TKIs in a community-based practice can be
as favorable as those treated in a rigorously conducted clinical trial.
Molecular monitoring is critical to successful treatment of pa-
tients with CML, particularly because numerous studies have
demonstrated the prognostic signiﬁcance of early cytogenetic and
molecular responses in clinical trials.3,23-27 A recent study demon-
strated that a higher frequency of molecular monitoring was asso-
ciated with a lower rate of progression and longer progression-free
survival, which highlights the importance of response monitoring in
the treatment of CML outside of trials as well.22 The frequency of
response monitoring in this analysis was lower than that recom-
mended by the NCCN or ELN.13,14 Only 21% of patients had a
molecular assessment within the ﬁrst 3 months of starting TKI
therapy, even though all patients should have been tested in thisClinical Lymphoma, Myeloma & Leukemia October 2015early time frame. Both molecular and cytogenetic assessments are
recommended for many patients (both those responding to therapy
and those with rising BCR-ABL levels), yet only 60% of patients had
either assessment at any time during the period that was captured in
this analysis. The lapses in monitoring observed here may identify a
need to improve the frequency of response monitoring in the
community setting. Therefore, MSH/USON is attempting to
improve the adherence to monitoring in the EHR through an
automated alert added to the iKM EHR system.
Adherence to oral TKI therapy is essential to the achievement of
optimal response and the prevention of disease progression; how-
ever, nonadherence has been shown to be problematic for patients
with CML.16,17,28 For this reason, when patients do not achieve
treatment milestones, NCCN guidelines recommend that physi-
cians assess patients’ adherence before making any treatment
adjustments.13 With few data available regarding the association
between adherence and response in a community setting, we chose
to investigate adherence in patients with CML. An association be-
tween response to TKIs and adherence was limited as a result of
small sample sizes, as low frequency of molecular monitoring was
observed in this analysis. In addition, by calculating adherence in
this study on the basis of days of supply using physician prescription
records, we did not account for dose modiﬁcation to manage
adverse events or the extent of actual dispensation to the patient.
Our study is subject to inherent limitations of retrospective an-
alyses based on electronic medical records, in that databases may
contain inaccurate or missing data. Because this study was not an
analysis of randomized patients, unmeasured confounders could
have biased the comparisons. Furthermore, many PCR assessments
were reported as log reduction from baseline or as a BCR-ABL level
not on the IS, suggesting that this test was not widely available
during the study period. Speciﬁc to this study, the data that were
based on univariate analyses will require further investigation with a
larger population and multivariable models. Small sample sizes and
the lack of frequent response monitoring limited the comparison of
outcomes between dasatinib and nilotinib. This study design also
did not allow for comparison of transformation to AP or BP because
only patients with  18 months of follow-up data were included,
thus excluding patients with transformation and death within 18
months.
Conclusion
Among community-based CML patients who received ﬁrst-line
TKI therapy, patients treated with either dasatinib or nilotinib
achieved higher rates of CCyR and MMR, had faster time to MMR,
and had a lower rate of treatment discontinuation within the ﬁrst 18
months relative to patients treated with imatinib. The frequency of
cytogenetic and molecular monitoring of this same population was
lower than that recommended by current guidelines established by
the NCCN and ELN, limiting the potential to identify patients at
risk. Undermonitoring also hindered the comparison of outcomes
between dasatinib and nilotinib and the establishment of a rela-
tionship between adherence and response. These ﬁndings under-
score the importance of closely monitoring patients with CML;
therefore, MSH/USON is working to improve the frequency of
monitoring through updated protocols, educational activities, and
reminders within the electronic medical record.
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 Three TKIs are approved for patients with newly diagnosed
CML: ﬁrst-generation TKI imatinib and second-generation TKIs
dasatinib and nilotinib.
 It is unclear whether responses and outcomes of CML patients
treated with ﬁrst-line TKIs in clinical trials are similar to those
treated in a community setting.
 Presented here is a retrospective observational study of patients
with CML treated with TKIs in the ﬁrst-line setting in the com-
munity clinical practices of MSH/USON. Data were extracted
fromMSH/USON’s iKM EHR system, electronic medical record
chart review, and the Social Security Death Master File.
 Dasatinib and nilotinib provided higher rates of CCyR and
MMR relative to imatinib in a community setting as observed in
descriptive and univariate analyses, consistent with ﬁndings in
major ﬁrst-line trials.
 Patients treated with either dasatinib or nilotinib had faster time
to MMR and a lower rate of all-cause treatment discontinuation
relative to patients treated with imatinib.
 Studies with more sensitive measurements of adherence are
needed to establish the relationship between adherence and
response.
 The frequency of cytogenetic and molecular monitoring was
lower here than recommendations by current guidelines.
 Uniform reporting of BCR-ABL levels using IS should be a goal
in the United States.
 MSH/USON is working to improve compliance with response
monitoring guidelines through educational activities and re-
minders within the iKM EHR system.Acknowledgments
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